Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cipla
Federal Trade Commission
Express Scripts
Cerilliant
Moodys
Covington
Merck
McKinsey

Generated: February 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN

« Back to Dashboard

Clinical Trials for Empagliflozin

Trial ID Title Status Sponsor Phase Summary
NCT00881530 Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension Completed Boehringer Ingelheim Phase 2 The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.
NCT00885118 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM) Completed Boehringer Ingelheim Phase 2 The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
NCT01001962 Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics Not yet recruiting Aristotle University Of Thessaloniki Phase 4 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT01111318 Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function Completed Boehringer Ingelheim Phase 1 The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Empagliflozin

Condition Name

Condition Name for Empagliflozin
Intervention Trials
Diabetes Mellitus, Type 2 43
Healthy 29
Heart Failure 12
Type 2 Diabetes Mellitus 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Empagliflozin
Intervention Trials
Diabetes Mellitus 82
Diabetes Mellitus, Type 2 72
Heart Failure 18
Diabetes Mellitus, Type 1 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Empagliflozin

Trials by Country

Trials by Country for Empagliflozin
Location Trials
United States 480
Canada 96
Germany 50
Australia 19
Japan 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Empagliflozin
Location Trials
Texas 29
Florida 25
California 24
Georgia 23
Ohio 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Empagliflozin

Clinical Trial Phase

Clinical Trial Phase for Empagliflozin
Clinical Trial Phase Trials
Phase 4 30
Phase 3 37
Phase 2/Phase 3 4
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Empagliflozin
Clinical Trial Phase Trials
Completed 58
Recruiting 40
Not yet recruiting 31
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Empagliflozin

Sponsor Name

Sponsor Name for Empagliflozin
Sponsor Trials
Boehringer Ingelheim 83
Eli Lilly and Company 47
University Hospital, Basel, Switzerland 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Empagliflozin
Sponsor Trials
Industry 147
Other 83
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Express Scripts
Cerilliant
Covington
McKesson
Citi
Deloitte
Teva
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.